Drug Company Will Send Experimental Drug To Dying St. Jude Patient

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

Photo courtesy of CNN.

Chimerix has notified St. Jude that it will send the drug that could save 7-year-old Josh Hardy’s life. The company will send the drug known as brincidofovir within the next 48 hours.

St. Jude said in a statement:

This drug is experimental and has not yet been approved by the FDA and the safety and effectiveness of the medication has not yet been established for use in children.  For this reason, it  will be administered under a new treatment protocol as approved by a committee charged with compliance to federal and institutional regulations for clinical research (IRB).  It is also important to understand that this remains a critical and complex medical situation.

St. Jude will continue to pursue state-of-the-art treatment for Josh and all of our patients.  We are grateful for the efforts of Chimerix, the FDA and many others who worked to achieve this outcome. We ask that you continue to keep Josh and his family in your thoughts.

It was recently reported that 7-year-old Josh Hardy was having heart and kidney failure due to a rare virus, and the only thing that could save him was an experimental drug that Chimerix, a pharmaceutical company, was refusing to provide.

They have no reverse that decision and will give the life-saving experimental drug to Hardy.

To read the rest of the story, visit our affiliate station’s website WREG – Channel 3 by clicking here.